Parabilis priced an upsized $670 million IPO on Nasdaq, marking the largest-ever biotech listing from a venture-backed company. The company sold 33.5 million shares at $20 each, and also disclosed a concurrent private placement tied to Regeneron. The capital infusion supports Parabilis’ oncology strategy, anchored by zolucatetide (FOG-001) across multiple solid tumor studies. The broader market context in the coverage pointed to selective investor appetite for well-funded clinical-stage biotechs and large equity raises after earlier-year IPO constraints.